Spots Global Cancer Trial Database for ctdna
Every month we try and update this database with for ctdna cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer | NCT06364371 | Predictive Canc... Pathologic Comp... | Medical examina... | 18 Years - 80 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Clinical Application of ctDNA in Early Screening of Breast Cancer | NCT03973034 | Breast Cancer | Low depth whole... | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Localized Leiomyosarcoma Biomarker Protocol | NCT04925089 | Leiomyosarcoma | Blood and Tissu... | - | University of Michigan Rogel Cancer Center | |
| Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer | NCT05788744 | Resectable Panc... | ctDNA | - | Copenhagen University Hospital at Herlev | |
| the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer | NCT05131243 | Colorectal Canc... Colorectal Canc... | Chemotherapy ti... Chemotherapy ti... | 18 Years - | Fujian Cancer Hospital | |
| An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma | NCT05759325 | Squamous Cell C... | 18 Years - 80 Years | Guangzhou Institute of Respiratory Disease | ||
| Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma | NCT03896620 | Sarcoma | Preoperative RT Postoperative R... Chemotherapy Surgery | 18 Years - | Medical College of Wisconsin | |
| Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study | NCT06105177 | Lung Cancer | 18 Years - | Catharina Ziekenhuis Eindhoven | ||
| Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia | NCT05050890 | Breast Neoplasm | ctDNA level dur... | 18 Years - | Instituto Brasileiro de Controle do Cancer | |
| ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer | NCT04752930 | Colorectal Canc... Peritoneal Meta... | ctDNA monitorin... Imageology | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Concordance Between ctDNA Assay and FoundationOne | NCT02620527 | Circulating Tum... Cancer Neoplasms Genomic Testing Genomic Alterat... | 18 Years - | Foundation Medicine | ||
| The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | NCT06283875 | Ovarian Cancer | 18 Years - 80 Years | Geneplus-Beijing Co. Ltd. | ||
| Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma | NCT03896620 | Sarcoma | Preoperative RT Postoperative R... Chemotherapy Surgery | 18 Years - | Medical College of Wisconsin | |
| Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | NCT04726800 | Colorectal Canc... | 18 Years - 80 Years | Karolinska Institutet | ||
| ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC | NCT05198154 | Advanced Lung N... | ctDNA detection | 18 Years - 75 Years | Second Xiangya Hospital of Central South University | |
| Evolution of Multiple Primary Lung Cancer (Evolution) | NCT04326751 | Multiple Primar... Lung Cancer Non Small Cell ... | 18 Years - 80 Years | Peking University People's Hospital | ||
| Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence | NCT05823584 | Hepatocellular ... | 20 Years - | TCM Biotech International Corp. | ||
| Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | NCT05740943 | Stage III NSCLC Surgery | Lorlatinib | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer | NCT06307938 | Colorectal Canc... Colorectal Aden... | liquid biopsy | 18 Years - | Helse Nord-Trøndelag HF | |
| Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) | NCT02856893 | NSCLC | Osimertinib Gefitinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer | NCT03076502 | Neoplasms, Gast... | 18 Years - 80 Years | RenJi Hospital | ||
| Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study | NCT06105177 | Lung Cancer | 18 Years - | Catharina Ziekenhuis Eindhoven | ||
| NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | NCT03771404 | Non Small Cell ... | blood sampling | 18 Years - | Hellenic Oncology Research Group | |
| The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer | NCT03416478 | Colorectal Canc... ctDNA Surveillance | ctDNA test | 18 Years - | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | NCT05740943 | Stage III NSCLC Surgery | Lorlatinib | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA | NCT05375370 | Hepatocellular ... | circulating tum... | 18 Years - | University Hospital, Rouen | |
| Asian Multicenter Prospective Study of ctDNA Sequencing | NCT05099978 | Cervical Cancer Ovarian Clear C... Nasopharyngeal ... Ovarian Cancer Endometrial Can... Triple Negative... | NGS analysis of... | 18 Years - | National Cancer Center, Japan | |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | NCT04561453 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... Intrahepatic Ch... Perihilar Chola... Extrahepatic Ch... Hilar Cholangio... Distal Bile Duc... | Multi-Platform ... | 18 Years - | University of Washington | |
| Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease | NCT02612350 | Mutation Neoplasms | ctDNA Analysis ... | 18 Years - | Pathway Genomics | |
| Diagnosis; Objective RespOnse; THErApy | NCT05036564 | Primary CNS Lym... | Lumbar puncture | 18 Years - | IRCCS San Raffaele | |
| Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq) | NCT05415670 | Pulmonary Nodul... Whole-genome Me... | Whole-genome Me... | 20 Years - 75 Years | Geneplus-Beijing Co. Ltd. | |
| Project CADENCE (CAncer Detected Early caN be CurEd) | NCT05633342 | Thoracic Cancer Ovarian Cancer Liver Cancer Prostate Cancer Gastric Cancer Colorectal Canc... Breast Cancer Esophageal Canc... Pancreatic Canc... | 21 Years - | MiRXES Pte Ltd | ||
| Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer | NCT05356585 | Colorectal Canc... Rectal Cancer | SignateraTM ass... | 18 Years - | Case Comprehensive Cancer Center | |
| SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers | NCT05582122 | Oropharynx Squa... | HPV16 Ct-DNA do... | 18 Years - | UNICANCER | |
| DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer | NCT04567420 | Breast Cancer | Palbociclib Fulvestrant Adjuvant Therap... | - | Criterium, Inc. | |
| ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS | NCT03172156 | Non-small Cell ... | ctDNA detection | 18 Years - 75 Years | Sun Yat-sen University | |
| Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease | NCT02612350 | Mutation Neoplasms | ctDNA Analysis ... | 18 Years - | Pathway Genomics | |
| Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy | NCT04138628 | Bladder Cancer Bladder Cancer,... | Atezolizumab | 18 Years - | Aarhus University Hospital | |
| CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer | NCT05210283 | Colorectal Canc... | MRD | 18 Years - | Exact Sciences Corporation | |
| NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | NCT03771404 | Non Small Cell ... | blood sampling | 18 Years - | Hellenic Oncology Research Group | |
| Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer | NCT05058183 | Breast Cancer | ctDNA | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors | NCT03596593 | Solid Tumor | SPANOM (identif... | 18 Years - | Peking University | |
| ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial | NCT05743959 | Biliary Tract C... | No intervention | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer | NCT05629442 | Rectal Cancer Non Metastatic ... | ctDNA | 18 Years - | Massachusetts General Hospital | |
| Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer | NCT05788744 | Resectable Panc... | ctDNA | - | Copenhagen University Hospital at Herlev | |
| ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) | NCT06242418 | Colon Cancer | FOLFOXIRI XELOX | 18 Years - 75 Years | West China Hospital | |
| Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer | NCT05976932 | Ovarian Cancer | pegylated lipos... | 18 Years - | Fudan University | |
| A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | NCT04786600 | Metastatic Colo... | Signatera ctDNA... pre-specified s... | 18 Years - 99 Years | University of Florida | |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | NCT05419089 | HPV-positive Or... | Robotic surgery | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA | NCT05797077 | Colorectal Canc... Liver Metastase... Circulating Tum... Cancer, Therapy... | Colorectal rese... FOLFOX chemothe... Capecitabine | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | NCT05031975 | Colorectal Canc... | Irinotecan Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | NCT03771404 | Non Small Cell ... | blood sampling | 18 Years - | Hellenic Oncology Research Group | |
| Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments | NCT06025045 | Ovarian Cancer ... Ovarian Cancer ... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | ||
| Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials | NCT02994511 | Cancer | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | ||
| Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer | NCT05529615 | Colon Cancer Circulating Tum... | detection of ct... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence | NCT04506398 | Hepatocellular ... Liver Transplan... | liver transplan... ctDNA whole exome seq... | 18 Years - 80 Years | RenJi Hospital | |
| Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer | NCT06307938 | Colorectal Canc... Colorectal Aden... | liquid biopsy | 18 Years - | Helse Nord-Trøndelag HF | |
| DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer | NCT04567420 | Breast Cancer | Palbociclib Fulvestrant Adjuvant Therap... | - | Criterium, Inc. | |
| PRecision Oncology Evidence Development in Cancer Treatment - Liquid | NCT05057234 | Cancer | FoundationOne l... Quality of life... | 18 Years - | British Columbia Cancer Agency | |
| Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT) | NCT06367751 | Advanced Solid ... | ctDNA measureme... | 18 Years - | University Hospital, Basel, Switzerland | |
| Localized Leiomyosarcoma Biomarker Protocol | NCT04925089 | Leiomyosarcoma | Blood and Tissu... | - | University of Michigan Rogel Cancer Center | |
| MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. | NCT04841811 | Lung Cancer | Almonertinib | 18 Years - 70 Years | Guangdong Association of Clinical Trials | |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | NCT05419089 | HPV-positive Or... | Robotic surgery | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| ctDNA for Early Detection of Recurrence in Melanoma | NCT06246227 | Melanoma | 18 Years - | Herlev and Gentofte Hospital | ||
| Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients | NCT03881384 | Breast Neoplasm... | ctDNA level dur... | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | |
| Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies. | NCT04853420 | Cancer | 18 Years - | University of Leicester | ||
| Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion | NCT02579278 | Cancer Rectal Cancer | Blood sample (m... Blood sample (m... | 16 Years - | Imperial College London | |
| Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | NCT04259944 | Colon Cancer | CAPOX Capecitabine FOLFIRI | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC | NCT05641870 | Lung Cancer Stage III Lung ... Unresectable Lu... | Sample collecti... Characterizatio... Chemoradiation ... Genomic and met... | 18 Years - | Parc de Salut Mar | |
| ctDNA Based MRD Testing for NAC Monitoring in TNBC | NCT06230185 | TNBC - Triple-N... Minimal Residua... | 18 Years - | Personalis Inc. | ||
| ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial | NCT04084249 | Colorectal Canc... Colo-rectal Can... ctDNA Gastro-Intestin... Colorectal Neop... Gastrointestina... Gastrointestina... Digestive Syste... Digestive Syste... Colonic Disease... Colonic Neoplas... Colonic Cancer Rectal Diseases Rectal Neoplasm... Rectal Cancer | ctDNA-analysis Intensified Fol... | 18 Years - | University of Aarhus | |
| ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer | NCT05629442 | Rectal Cancer Non Metastatic ... | ctDNA | 18 Years - | Massachusetts General Hospital | |
| XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma | NCT05494060 | Carcinoma Gastrointestina... Stomach Cancer Gastroesophagea... Digestive Syste... Gastric Cancer Gastrointestina... | Anlotinib hydro... Penpulimab Inje... XELOX | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | NCT03771404 | Non Small Cell ... | blood sampling | 18 Years - | Hellenic Oncology Research Group | |
| Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | NCT04259944 | Colon Cancer | CAPOX Capecitabine FOLFIRI | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | NCT06178809 | Hepatocellular ... | 18 Years - 80 Years | Singlera Genomics Inc. | ||
| Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer | NCT04014465 | Lung Cancer Esophageal Canc... | 18 Years - | ChineseAMS | ||
| Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention | NCT05635630 | Metastatic Colo... No Evidence of ... ctDNA Monitorin... | ctDNA and adjuv... ctDNA | 18 Years - 85 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
